Lindus Health and Acinonyx Bio are launching a clinical trial to investigate Acinonyx Bio’s topical cream’s ability to treat inflammatory acne by targeting Propionibacterium acnes (P. acnes).
In in vitro studies, Acinonyx Bio’s topical cream, ACX, killed P. acnes as rapidly as benzoyl peroxide.
The clinical trial will recruit patients with moderate to severe inflammatory acne and will be carried out under a decentralized clinical trial model. Participants will use the investigational product for a period of six weeks and provide photos for medical assessment as well as feedback on the effectiveness of the topical cream and their satisfaction with the product.
“We are optimistic about the development of our topical cream and the effect it will have on patients,” says Alex Michalow, CEO at Acinonyx Bio, in a news release. “We are incredibly excited to be working with Lindus Health to bring our study to life and aid in the overall journey of potentially bringing a safer alternative to the hands of individuals suffering from inflammatory acne.”
